We are live on ! Find out more
MLNT

Melinta Therapeutics, Inc. Common Stock
MLNT

Delisted

MLNT was delisted on the 10th of January, 2020.

Back to rankings

52 hedge funds and large institutions have $18.6M invested in Melinta Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more call options, than puts

Call options by funds: $254K | Put options by funds: $217K

0% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 19

31% less capital invested

Capital invested by funds: $26.9M → $18.6M (-$8.34M)

32% less funds holding

Funds holding: 77 → 52 (-25)

86% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 29

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
52
Holders Change
-25
Holders Change %
-32.47%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
19
Reduced
19
Closed
29
Calls
$254K
Puts
$217K
Net Calls
+$37K
Net Calls Change
+$30K

Top Buyers

1
DM
Deerfield Management
New York
+$1.57M
2
GIM
Granahan Investment Management
Massachusetts
+$905K
3
Stifel Financial
Stifel Financial
Missouri
+$832K
4
ZIM
Zacks Investment Management
Illinois
+$829K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$445K

Top Sellers

1
OH
Oikos Holdings
New York
-$13.2M
2
SFM
Sphera Funds Management
Israel
-$1.28M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$782K
4
Deutsche Bank
Deutsche Bank
Germany
-$769K
5
First Manhattan
First Manhattan
New York
-$749K
Name Holding Trade Value Shares
Change 		Change in
Stake
IP
1
Isthmus Partners
Wisconsin
$7.66M +$440K +81,072 +2,702%
BlackRock
2
BlackRock
New York
$1.71M -$137K -25,266 -5%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$1.53M -$782K -144,081 -25%
DM
4
Deerfield Management
New York
$1.27M +$1.57M +290,172 +435%
Stifel Financial
5
Stifel Financial
Missouri
$950K +$832K +153,400 +134%
GIM
6
Granahan Investment Management
Massachusetts
$813K +$905K +166,831 +268%
Vanguard Group
7
Vanguard Group
Pennsylvania
$797K +$445K +81,939 +58%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$551K +$4.17K +769 +0.5%
ZIM
9
Zacks Investment Management
Illinois
$542K +$829K +152,787 New
Renaissance Technologies
10
Renaissance Technologies
New York
$454K -$347K -64,004 -33%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$438K +$215K +39,631 +47%
State Street
12
State Street
Massachusetts
$383K +$85.6K +15,778 +17%
Northern Trust
13
Northern Trust
Illinois
$278K -$1.73K -319 -0.4%
SIM
14
Spark Investment Management
New York
$159K +$100K +18,460 +70%
Millennium Management
15
Millennium Management
New York
$139K -$440K -80,989 -67%
Charles Schwab
16
Charles Schwab
California
$125K +$4.02K +740 +2%
BS
17
Boenning & Scattergood
Pennsylvania
$124K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$98K -$6.41K -1,182 -4%
New York State Common Retirement Fund
19
New York State Common Retirement Fund
New York
$66K +$66.6K +12,268 +196%
Citadel Advisors
20
Citadel Advisors
Florida
$53K -$1.97K -363 -2%
TCIM
21
TIAA CREF Investment Management
New York
$53K +$42.6K +7,842 +112%
FSA
22
Franklin Street Advisors
North Carolina
$48K – – –
California State Teachers Retirement System (CalSTRS)
23
California State Teachers Retirement System (CalSTRS)
California
$40K – – –
Creative Planning
24
Creative Planning
Kansas
$40K +$42.1K +7,754 +225%
AG
25
Algert Global
California
$39K +$59.1K +10,898 New
1
2 3

MLNT Hedge Fund Activity: Q1 2019 in Review

52 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q1 2019, worth a combined $18.6M — down 31% from $26.9M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of MLNT and 4 opened new positions — a net loss of 25 holders — while 19 trimmed existing stakes and 19 added.

The largest buyer was Deerfield Management, adding an estimated $1.57M. The largest seller was Oikos Holdings, exiting entirely with an estimated $13.2M sold.

  • 52 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q1 2019, down from 77 in Q4 2018.
  • Funds reported $18.6M of Melinta Therapeutics, Inc. Common Stock stock for Q1 2019, down 31% quarter-over-quarter.
  • 4 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q1 2019 and 29 closed out, a net change of -25 holders.
  • The largest Melinta Therapeutics, Inc. Common Stock buyer in Q1 2019 was Deerfield Management, an estimated $1.57M added.
  • The largest Melinta Therapeutics, Inc. Common Stock seller in Q1 2019 was Oikos Holdings, an estimated $13.2M sold.

Based on aggregated 13F filings for Q1 2019.